Drugs / VET3-TGI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06444815 | Sep 2024 → Sep 2027 expected | cervical cancer, colorectal cancer, cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma +6 | KaliVir Immunotherapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-07-01 | KaliVir Immunotherapeutics | Regulatory KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors kalivir.com ↗
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced that the FDA has cleared the Investigational New Drug (IND) application for the STEALTH-001 study of VET3-TGI in patients with incurable, advanced solid tumors. |
| 2023-05-19 | KaliVir Immunotherapeutics | Results KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kalivir.com ↗ |
| 2023-04-17 | KaliVir Immunotherapeutics | Results KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Potent Therapeutic Activity for Oncolytic Therapy VET3-TGI at the American Association for Cancer Research (AACR) Annual Meeting kalivir.com ↗
VET3-TGI demonstrated potent therapeutic activity, even at doses several logs below equivalent clinical doses and in the presence of pre-existing anti-viral immunity. |
| 2022-11-10 | KaliVir Immunotherapeutics | Results KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting kalivir.com ↗
This systemic delivery resulted in between 60 to 90% complete responses in different immunocompetent mouse tumor models. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VET3-TGI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06444815 ↗ |
| Route | Other | “administered by direct injection into tumor(s)” NCT06444815 ↗ |